Positive on Aurobindo Pharma; look at Glenmark, Lupin: Tulsian

SP Tulsian of sptulsian.com told CNBC-TV18, "Lupin's news is very positive. All three plants, Pithampur, Aurangabad and Tarapur have got clear observations, infact the sword was hanging on Lupin and that has not been seen participating in the rally because of their Goa plant concern. Goa still continues to remain an unresolved issue but Lupin now will be seeing a big relief because of this." "However, in Aurobindo Pharma because of two plants, one has got clean chit from the US FDA but on the other one there are some issues but actually I have been keeping quite a positive stance on the stock. Looking at lot of US approvals received by this company in the past maybe about three months, those are the small drugs but they have all got good approvals maybe about 10-12 US FDA approvals in the last quarter or so. So positive view continues to be on Aurobindo Pharma but because of other unit which has come under observation, one unit is getting clean chit, so one has to be cautious," he said."I am quite impressed with Glenmark Pharma and Lupin at this stage because the results of Glenmark is behind us, we have not found anything negative on that account. Some concerns continue to remain on Latin America or Venezuela, but those are the smaller ones. So maybe right now one can look for Lupin followed by Glenmark, looking at the share price at which they all been ruling at."